Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Open accessThe DOI matches its Crossref record; 198 of the 200 references it cites were found in a registry or an index.
Abstract
The blood–brain barrier (BBB) keeps neurotoxic plasma-derived components, cells, and pathogens out of the brain. An early BBB breakdown and/or dysfunction have been shown in Alzheimer’s disease (AD) before dementia, neurodegeneration and/or brain atrophy occur. However, the role of BBB breakdown in neurodegenerative disorders is still not fully understood. Here, we examine BBB breakdown in animal models frequently used to study the pathophysiology of AD, including transgenic mice expressing human amyloid-β precursor protein, presenilin 1, and tau mutations, and apolipoprotein E, the strongest genetic risk factor for AD. We discuss the role of BBB breakdown and dysfunction in neurodegenerative process, pitfalls in BBB measurements, and how targeting the BBB can influence the course of neurological disorder. Finally, we comment on future approaches and models to better define, at the cellular and molecular level, the underlying mechanisms between BBB breakdown and neurodegeneration as a basis for developing new therapies for BBB repair to control neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAA is caused by A 𝛃 deposition in the vascular wall of small brain arteries and capillaries and develops as a result of an imbalance between A 𝛃 production and clearance, particularly faulty transvascular and perivascular clearance of A 𝛃 from the brain (318, 420, 581, 640).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, microvascular endothelial aging also disrupts the blood-brain barrier, which promotes neuroinflammation, exacerbating cognitive decline”
From Single-cell RNA sequencing identifies senescent cerebromicrovascular endothelial cells in the aged mouse brain (2020) · cites this paper as Montagne et al. 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss of claudins is associated with BBB breakdown in human neurodegenerative disorders (155, 569) and acute CNS diseases (692), as well as in animal models of these diseases (420), as discussed below.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As previously reviewed, FDG-PET reflects mainly the transport activity of GLUT1 BBB transporter (420, 569).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides FDG-PET and verapamil-PET that have been used to test functions of BBB GLUT1 transporter and activity of ABCB1 (P-gp) efflux transporter in AD and PD (420, 569), respectively”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., & Zlokovic, B. V. (2013) · Nature Communications · doi:10.1038/ncomms3932 · Cited by 589
Self-citationRetractedSokoloff, L., Reivich, M., Kennedy, C., Rosiers, M. H. D., Patlak, C. S., Pettigrew, K. D., Sakurada, O., & Shinohara, M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10649.x · Cited by 6,000 · cited 6×
“…for glucose-6-phosphate isomerase and therefore cannot be converted into fructose-6-phosphate, a necessary step to enter the glycolytic pathway or Krebs cycle, as shown by multiple independent studies (Sols and Crane, 1954; Sokoloff et al., 1977; McDougal et al., 1990; Rokka et al., 2017).”
BackgroundInfluentialIliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Wardlaw, J. M., Smith, E. E., Biessels, G. J., Cordonnier, C., Fazekas, F., Frayne, R., Lindley, R. I., O'Brien, J. T., Barkhof, F., Benavente, O. R., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70124-8 · Cited by 5,544 · cited 13×
“…in APPSw/0 mice (at 1, 3, and 6 mo of age; Ujiie et al., 2003; Paul et al., 2007; Sagare et al., 2013) before Aβ deposition, cerebral amyloid angiopathy (CAA), and/or behavioral deficits that develop later (at 7–10, 9–12, and 6–9 mo of age, respectively; Domnitz et al., 2005; Webster et al., 2014).”
BackgroundInfluentialSleep Drives Metabolite Clearance from the Adult Brain
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., et al. (2013) · Science · doi:10.1126/science.1241224 · Cited by 5,411
Structural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 1×
“Because of minimal glucose-6-phosphatase activity in the brain (Hers and De Duve, 1950; Sokoloff et al., 1977) and low 2DG-6P membrane permeability, 2DG-6P remains trapped in brain cells (Huang and Veech, 1985; Southworth et al., 2003) and is eliminated very slowly from the brain.”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 2×
“, 2001; Armstrong, 2008) and imaging studies in the living human brain (Bateman et al., 2012; Benzinger et al., 2013; Fleisher et al., 2015), respectively.”
BackgroundOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“…et al., 2002; Zipser et al., 2007; Hultman et al., 2013; Zonneveld et al., 2014; Halliday et al., 2016), diminished regional BBB uptake of glucose (Ossenkoppele et al., 2013; Protas et al., 2013), and early neurovascular dysfunction (Rei- man et al., 2004; Sheline et al., 2010; Thambisetty et…”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“3157JEM Vol. 214, No. 11 (PIC ALM) protein encoded by the PIC ALM gene, a highly validated genetic risk factor for human AD (Harold et al., 2009; Lambert et al., 2009; Huang et al., 2017), accelerates Aβ deposition in APPSw/0 mice, consistent with its critical role in regulating LRP1-mediated Aβ…”
Research works printed but not linked: 2
- Hachinski, 2016, Correction. World Stroke Organization. Stroke and potentially preventable dementias proclamation: updated World Stroke Day proclamation, Stroke., 47, e37
- Holtzman, 2000, Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer’s disease model, Ann. Neurol., 47, 739, 10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8 · doi:10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8
Cited by
Items 601–688 of 688
Velmurugan, G. V., Ly, H., Sharma, S., Verma, N., Despa, S. I., Nelson, P. T., Goldstein, L. B., & Despa, F. (2020) · doi:10.21203/rs.3.rs-52604/v1
“This pathway of Aβ clearance from the brain is reduced early in the onset of AD causing Aβ deposition in capillary beds [46].”
BackgroundAktuelle Befunde zur Koinzidenz von zerebraler Amyloidangiopathie und Alzheimer-Erkrankung
Haußmann, R., Homeyer, P., Donix, M., & Linn, J. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01213-x
Xiang, S., Johnson, T. S., Dong, T., Huang, Z., Cheng, M., Wang, T., Yang, K., Ni, D., Huang, K., & Zhang, J. (2020) · Research Square · doi:10.21203/rs.3.rs-26385/v1
“16 allow the access of virus or bacteria to AD brain (Cai et al., 2018; Devanand, 2018; Montagne et al., 2017; Readhead et al., 2018).”
BackgroundAbounader, R., & Mulcahy, E. Q. X. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737839792.793575547
Imaging blood-brain barrier function in aging
Verheggen, I. C. M. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210601iv
Johnson, T. S., Xiang, S., Dong, T., Huang, Z., Cheng, M., Wang, T., Yang, K., Ni, D., Huang, K., & Zhang, J. (2020) · Research Square · doi:10.21203/rs.3.rs-26385/v2
Johnson, T. S., Xiang, S., Dong, T., Huang, Z., Cheng, M., Wang, T., Yang, K., Ni, D., Huang, K., & Zhang, J. (2020) · doi:10.21203/rs.3.rs-92026/v1
Sobti, N., & Bayraktar, G. (2023) · Journal of Student Research · doi:10.47611/jsr.v11i3.1644 · Cited by 1
Three Neurodegenerative Diseases: A Single Hope
Youssef, S. H., Atalah, H. N., Badawy, M. T., El‐Fawal, H. A. N., & Salama, M. (2023) · Springer eBooks · doi:10.1007/978-981-19-3949-5_3-1
Cognitive Function Involving Glial Cells: The Surprising Role of Astrocytes
Boulbaroud, S., Khalki, H., & Azzaoui, F.-Z. (2023) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/978-1-6684-9675-6.ch003 · Cited by 1
Analysis of transporter activity in an Alzheimer’s disease blood-brain barrier cell model
Chaves, J. (2024) · Queensland University of Technology · doi:10.5204/thesis.eprints.248279
Shao, X., Shou, Q., Felix, K., Ojogho, B., Jiang, X., Gold, B. T., Herting, M. M., Goldwaser, E. L., Kochunov, P., Hong, L. E., et al. (2024) · eLife · doi:10.7554/elife.96155.2.sa0
Kanuri, S. H., & Sirrkay, P. J. (2024) · Neurology Letters · doi:10.61186/nl.3.3.19
Adu-Agyarko, A., Etekochay, M. O., Gurajala, S., Oduoye, M. O., & Majumdar, S. (2024) · Microbiology Independent Research Journal (MIR Journal) · doi:10.18527/2024118096
The blood–brain barrier: Gatekeeper and obstacle in neurodegenerative disorders
Bassiony, M., Ibrahem, M. A., Youssef, D. G., Elbadry, A. M. M., & Alaboudi, O. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00002-6
Zheng, J., Wang, J., Chen, L., Jiang, X., Zhang, X., Ai, W., Xie, Y., Wang, P., Lan, Z., & Ding, X. (2024) · Journal of Natural Medicines · doi:10.1007/s11418-024-01861-8
“Our findings suggest a potential mechanism involving Aβ 1-42 -induced cerebral inflammation and BBB disruption, leading to inflammatory factors entering the periphery and reaching the liver [31, 32].”
Quantum dots for the treatment of neurodegenerative disorders
Girija, S., Wilson, J., Ananthappan, P., & Vasantha, V. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24064-5.00001-9
Choe, Y. M., Choi, H., Keum, M., Lee, B. C., Suh, G., Kim, S. G., Kim, H. S., Hwang, J., Yi, D., & Kim, J. W. (2025) · Nutrients · doi:10.3390/nu17142321 · Cited by 1
“In addition, HDL-C appears to exert vasoprotective effects—such as maintaining endothelial function and reducing neurovascular inflammation—that may help preserve blood–brain barrier integrity and cerebral perfusion [17,46].”
Lin, A. (2025) · Scholarly review . · doi:10.70121/001c.143875
Retinal proteomics in neurodegeneration: Insights into ocular and brain disorders
Mirshahvaladi, S., Gaire, B. P., Kashani, S. A., Guha, A., Koronyo, Y., Fuchs, D.-T. S., You, Y., Black, K. L., Paulo, J. A., Graham, S. L., et al. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00291
“…brain-resident glial activation and peripheral immune cell infiltration, along with blood-brain barrier dysfunctions, characterize the pathophysiological processes of AD (Montagne et al., 2017; Zhong et al., 2018; Ni Chasaide and Lynch, 2020; Welikovitch et al., 2020; Pascoal et al., 2021).”
Peripheral CHI3L1 expression is associated with APOE ε4 status in early-onset Alzheimer’s disease
Steinmaurer, A., Breit, L., Stögmann, E., & König, T. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1730319
Nizari, S., Wells, J. A., Carare, R. O., Romero, I. A., & Hawkes, C. A. (2021) · Figshare · doi:10.6084/m9.figshare.13544422
Lee, S., Kim, S. E., Jang, H., Kim, J. P., Sohn, G., Park, Y. H., Ham, H., Gu, Y., Park, C. J., Kim, H. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26732656
Stevenson, M. E., Varghese, R., Hebron, M. L., Liu, X., Ratliff, N., Smith, A., Turner, R. S., & Moussa, C. (2024) · Figshare · doi:10.6084/m9.figshare.26589822
Additional file 1 of Mouse serum albumin induces neuronal apoptosis and tauopathies
Hou, S.-J., Huang, Y.-R., Zhu, J., Jia, Y.-B., Niu, X.-Y., Yang, J.-J., Yu, X.-L., Du, X.-Y., Liang, S.-Y., Cui, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26710775
Raut, S., Patel, R., & Al-Ahmad, A. J. (2021) · Figshare · doi:10.6084/m9.figshare.13545554
Wu, C., Yang, L., Feng, S., Zhu, L., Yang, L., Liu, T. C., & Duan, R. (2022) · Figshare · doi:10.6084/m9.figshare.21259535
Lv, X., Zhang, M., Cheng, Z., Wang, Q., Wang, P., Xie, Q., Ni, M., Shen, Y., Tang, Q., & Gao, F. (2023) · Figshare · doi:10.6084/m9.figshare.22620493
Additional file 2 of Mouse serum albumin induces neuronal apoptosis and tauopathies
Hou, S.-J., Huang, Y.-R., Zhu, J., Jia, Y.-B., Niu, X.-Y., Yang, J.-J., Yu, X.-L., Du, X.-Y., Liang, S.-Y., Cui, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26710778
Lobo, D. D., Nobre, R. J., Oliveira Miranda, C., Pereira, D., Castelhano, J., Sereno, J., Koeppen, A. H., Castelo-Branco, M. S., & Pereira de Almeida, L. (2020) · Figshare · doi:10.6084/m9.figshare.12900661
Reddy, J. S., Allen, M., Ho, C. C. G., Oatman, S. R., İş, Ö., Quicksall, Z., Wang, X., Jin, J., Patel, T. A., Carnwath, T., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14643245
Lobo, D. D., Nobre, R. J., Oliveira Miranda, C., Pereira, D., Castelhano, J., Sereno, J., Koeppen, A. H., Castelo-Branco, M. S., & Pereira de Almeida, L. (2020) · Figshare · doi:10.6084/m9.figshare.12900658
Stevenson, M. E., Varghese, R., Hebron, M. L., Liu, X., Ratliff, N., Smith, A., Turner, R. S., & Moussa, C. (2024) · Figshare · doi:10.6084/m9.figshare.26589819
Dean, T., Mendiola, A. S., Yan, Z., Meza-Acevedo, R., Cabriga, B., Akassoglou, K., & Ryu, J. K. (2024) · Figshare · doi:10.6084/m9.figshare.26706930
Faridar, A., Vasquez, M., Thome, A. D., Yin, Z., Xuan, H., Wang, J. H., Wen, S., Li, X., Thonhoff, J. R., Zhao, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21256713
Dean, T., Mendiola, A. S., Yan, Z., Meza-Acevedo, R., Cabriga, B., Akassoglou, K., & Ryu, J. K. (2024) · Figshare · doi:10.6084/m9.figshare.26706933
Additional file 3 of Mouse serum albumin induces neuronal apoptosis and tauopathies
Hou, S.-J., Huang, Y.-R., Zhu, J., Jia, Y.-B., Niu, X.-Y., Yang, J.-J., Yu, X.-L., Du, X.-Y., Liang, S.-Y., Cui, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26710781
Paradela, R. S., Justo, A. F. O., Paes, V. R., Leite, R. E. P., Pasqualucci, C. A., Grinberg, L. T., Naslavsky, M. S., Zatz, M., Nitrini, R., Jacob-Filho, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26656513
Stevenson, M. E. (2024) · DigitalGeorgetown (Georgetown University Library)
Relationships between blood-brain barrier disruption and Alzheimer’s disease biomarkers in aging
Denkinger, M. N. (2024) · eScholarship (California Digital Library)
Brookes, A. (2023) · Nottingham ePrints (University of Nottingham)
Characterising the role of ADAM17 in neuronal development in the context of Alzheimers disease
SENGUPTA, M. (2023) · Open Repository and Bibliography (University of Luxembourg)
Bates, J. (2025) · Nottingham ePrints (University of Nottingham)
Systemic Amyloid-β Metabolism in Alzheimer’s Disease
Dong-yu, F., Wang, J., Gu, B. J., Masters, C. L., & Wang, Y. (2026) · Springer eBooks · doi:10.1007/978-981-95-5222-1_7
Sun, J., Yuan, C., Xu, J., Zhu, J., Wang, N., Liu, Y., Wei, Q., Fang, W., Chen, Z., Wang, C., et al. (2026) · medRxiv · doi:10.64898/2026.01.10.26343600
Xie, J., Li, Y., Lu, J., Wang, W., Hou, Y., Huang, Y., Wu, H., Zhou, Y., & Li, J. (2026) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2026.02.001
Blood-based emerging biomarkers in early detection and diagnosis of Alzheimer’s disease
Anand, T., & Kumar, A. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.01.002
Minds and hearts: Cardio-neural crosstalk in cardiovascular and neurodegenerative diseases
Amro, A., & Lebeche, D. (2026) · Brain & Heart · doi:10.36922/bh025270033
Crossing the blood–brain barrier: exosomes in neurological research
Prakāsh, C., Saran, S., & Sharma, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36390-0.00019-1
Vautheny, A. (2019) · theses.fr (ABES) · doi:10.70675/1812d71aze8d9z48d6z87d1z5a23a4e81953
Freyssin, A. (2020) · theses.fr (ABES) · doi:10.70675/0db2e37dz547bz4731z852dz9b843c062cba
Mei, J., Xia, M., Peng, L., & Li, X. (2026) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2026.2645215 · Cited by 1
“Changes in microbial metabolites, including short-chain fatty acids (SCFAs), bile acids, and tryptophan derivatives, can modulate Aβ accumulation, tau pathology, and neurodegenerative processes (119–121).”
JCAD couples tight junction condensates to actin and RhoA to maintain the endothelial barrierPreprint
Jacobs, K. A., Jang, Y., Leung, F.-S., Mayo, L. N., Wittmann, T., Bush, J. O., & Kutys, M. L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.19.725802
Functional Pathological Features and Molecular Markers in Alzheimer’s Disease
Park, M.-N., Kim, H. W., Hong, J., Kim, J. K., Lee, S.-B., Baek, H. S., Kwak, S., Kwon, Y. J., Park, K., Jeon, J., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114720
“Synaptic proteins including synap-tophysin, PSD-95, and neurogranin provide insight into synaptic integrity [26,27], while BBB-associated proteins such as claudin-5, occludin, and PDGFR β reflect vascular dysfunction [28,29].”
Li, M.-Y., Lin, Y.-N., Chen, X.-X., Huang, K., Lin, J., Hua, Z., Ran, X., Shen, Y., Ban, C.-L., Xia, K.-X., et al. (2026) · LabMed discovery. · doi:10.1016/j.lmd.2026.100131
Zhang, C., Fang, D., & Zhang, L. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s619901
“…20 Currently inappropriate as mainline recommendation; evidence and logic weaker than “repair-first, then exploit” 20 Abbreviations : AAV, adeno-associated virus; B3GNT3, UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3. permeability interface at the blood-facing side (Figure 6B).”
Apoprotein E: Structural insights functionality and genetic variability
Tewari, S., & Ranade, S. D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40563-1.00008-9
Marsha, I. A., Setianingsih, H., Untari, N. K. S. D., & Liliawanti, L. (2026) · Jurnal Ners · doi:10.31004/jn.v10i2.54628
Gijs, M., Liang, L., Goezinne, F., Wang, Y., Foulquier, S., & Nuijts, R. M. M. A. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101492
Li, H., Li, Y., Liang, W., Wu, L., Han, C., Ren, Q., Liu, X., Cai, Y., & Wang, Z. (2026) · The FASEB Journal · doi:10.1096/fj.202601699rr
Yang, D., Guo, W., & Wang, B. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01930-9
“This barrier protection mechanism represents a fundamental way through which exercise-induced CTSS inhibition mitigates AD progression (Bohannon et al. 2025, Wani et al. 2021, Montagne et al. 2017).”
An, G. C., & Cockrell, C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.20.739661
Piqueras‐Losilla, D., García-Rey, A., Huguet-Lachon, A., Mayoral-Olmos, A., Campillo, I., Nufer, M., Chakraborty, M., Díaz-Maqueda, A., Barquero, N., González‐Barriga, A., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102929
Altveş, S., Güçlü, E., Yetisgin, E., Bilecen, K., & Vural, H. C. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12446-x
Bhat, S. S., Niranjan, V., BODHIREDDY, T., Kulkarni, S. R., Bandikatte, S. A., & Lavanya, C. (2026) · NeuroMarkers. · doi:10.1016/j.neumar.2026.100182
Drewel, M. (2026) · Digital Commons - USU (Utah State University) · doi:10.26076/ge9h-q704
Disruptions in glucose and amyloid-beta transport in mouse models manifesting metabolic syndromePreprint
Wang, L., Curran, G. L., Gali, C. C., Zhou, A. L., Min, P. H., Lowe, V. J., & Kandimalla, K. K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.15.741912
Hill, C., Morgan, H., Michopoulou, S. K., Niranjan, M., & Kipps, C. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71792
“In 26–28 The observation of this pattern in the A4 study, in which amyloid clearance was limited and solanezumab was not associated with increased hemorrhagic risk, suggests that it may reflect an underlying disease-related process rather than a purely treatment-induced effect.”
Targeting of NLRP3 Gln624/Ser658 by Carabrone attenuates inflammatory diseases
Jia, B., Abuduwaili, Z., Tang, H., Xiao, J., Zhang, R., Bao, X., Chen, J., Deng, S., Xu, Y., Yu, L., et al. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179299
Olazabal-Chias, M., Kratochvil, M., & Rojo, A. I. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106258
Impaired peptide amidation and risk of incident dementia in the Malmoe preventive project cohort
Kaufmann, P., Ilina, Y., Giontella, A., Press, M., Nägga, K., Hansson, O., Hampel, H. J., Bergmann, A., & Melander, O. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02173-7
Nanoparticles and the gut-microbiome: a dual strategy for oral brain delivery
Negahdari, R., Pouyanfar, N., Masoudifar, R., Aftabi, P., Fendereski, F., Anvari, Z., Masoumi, N., Faizi, M., & Ghorbani‐Bidkorbeh, F. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127477
Ficiarà, E. (n.d.) · Institutional Research Information System University of Turin (University of Turin)
Gao, Z., Li, J., & Jiang, D. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.122885
Diabetes‐Associated Cognitive Impairment: Pathophysiology and Emerging Therapies
Corbali, O., Menon, P., Corbali, H. I., Jagannathan, R., & Levey, A. I. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70487
“BBB impairment is also an early feature of Alzheimer's disease and may precede both brain atrophy and cognitive symptoms [77].”
Immune-endothelial crosstalk at the nexus of neuroinflammation and vascular dysfunction in aging
Cui, Z., Sun, H., Chen, Z., & Li, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1972284
Vascular drivers of cerebrospinal fluid movement and enlarged perivascular spaces
LeFevre, J. D., Vyas, Y., & Jefferson, A. L. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71927
“259 Thus, ePVSs may represent one of the earliest structural signs of clearance failure, predicting downstream protein accumulation, 15,16 neurodegeneration, 17,18 and cognitive decline.”
Developing precision nanoparticle-based drug delivery systems for Alzheimer's disease therapy
Shan, Q., Zheng, W., Yao, W., Bai, Y., Ding, W., Wang, J., & Bai, F. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103789
Li, J., Wang, Y., Liu, Y., 姬颖华, Lü, P., Yang, W., & Zhang, S. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.109709
Feng, J., Huang, X., Shi, Y., Gao, Y., Chen, J., Song, Z., Mao, X., Niu, S., Li, J., & Li, J. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1987345
Metadata
- Authors
- Montagne, A., Zhao, Z., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, Los Angeles, CA 1
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2017-10-23
- Volume
- 214
- Issue
- 11
- Pages
- 3151-3169
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC5679168
- OpenAlex
- W2766949297
- Cited by
- 672
- References
- 200
- Citations by year
- 2026: 54 · 2025: 56 · 2024: 93 · 2023: 82 · 2022: 82 · 2021: 90 · 2020: 91 · 2019: 76 · 2018: 46 · 2017: 2
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R01AG023084, R01NS090904, R01NS034467, R01AG039452, 5P01AG052350)
- Cure for Alzheimer’s Fund
- Alzheimer’s Association
- Fondation Leducq (16 CVD 05)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Alzheimer's disease, blood-brain barrier dysfunction, blood-brain barrier disruption, neurodegeneration, amyloid precursor protein, presenilin 1, tau mutations, apolipoprotein E, transgenic mouse model, BBB repair
- MeSH terms
- Alzheimer Disease, Animals, Blood-Brain Barrier, Disease Models, Animal, Humans, Mice, Transgenic, Mutation, Amyloid beta-Protein Precursor, tau Proteins, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.